NCT06199037View on ClinicalTrials.gov

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

June 24, 2026

Conditions
Alzheimer's Disease
Interventions
DRUG

SHR-1707

1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection

DRUG

SHR-1707 placebo

1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection

Trial Locations (1)

230000

RECRUITING

The First Affiliated hospital of USTC, Hefei

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY